Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-Infectious Choroiditis Subdivided into Its Diverse Pathophysiological Sub-Groups Is the Best-Known and Most Appropriate Nomenclature to Date for the Reclassification and Diagnosis of Former White Dot Entities.

Diagnostics (Basel, Switzerland)·2026
Same author

Ethnic Differences in the Presentation Patterns of Type 3 Macular Neovascularization.

Retina (Philadelphia, Pa.)·2026
Same author

Advancing glaucoma care: What's new in the 6th edition of the European Glaucoma Society guidelines.

European journal of ophthalmology·2026
Same author

Clinical Outcomes and Predictors of Mortality in Patients with Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Infections: A Retrospective Cohort Study.

Antibiotics (Basel, Switzerland)·2026
Same author

Opposing pathophysiological concepts in multiple evanescent white dot syndrome: The great MEWDS schism.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society·2025
Same author

European Glaucoma Society - Terminology and guidelines for glaucoma, 6th Edition.

The British journal of ophthalmology·2025

Related Experiment Video

Updated: May 29, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Tafluprost for glaucoma.

Marina Papadia1, Alessandro Bagnis, Riccardo Scotto

  • 1University of Genova, Eye Clinic, Department of Neurosciences, Ophthalmology and Genetics, Viale Benedetto XV, 5, 16148 Genova, Italy.

Expert Opinion on Pharmacotherapy
|September 16, 2011
PubMed
Summary
This summary is machine-generated.

Tafluprost, a new prostaglandin analogue eye drop, effectively lowers intraocular pressure (IOP) and offers improved tolerability. Its preservative-free formulation enhances patient compliance in glaucoma treatment.

Related Experiment Videos

Last Updated: May 29, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Glaucoma management relies on lowering intraocular pressure (IOP).
  • Patient compliance is crucial for chronic glaucoma therapy.
  • Prostaglandins are a primary drug class for glaucoma treatment.

Purpose of the Study:

  • To review tafluprost, a novel prostaglandin analogue.
  • To summarize tafluprost's efficacy and safety data.
  • To compare tafluprost with existing prostaglandin derivatives.

Main Methods:

  • Literature review of tafluprost.
  • Analysis of efficacy and safety data.
  • Inclusion of comparative studies with other prostaglandin analogues.

Main Results:

  • Tafluprost demonstrates a well-established IOP-lowering effect.
  • Tafluprost is the first topical prostaglandin available without preservatives.
  • Tafluprost has been available in Europe and Japan for over two years.

Conclusions:

  • Focus on drug efficacy and tolerability is increasing.
  • New formulations aim to reduce side effects and simplify administration.
  • Tafluprost offers a preservative-free option to improve patient compliance.